Tisagenlecleucel for acute lymphoblastic leukemia and diffuse large b-cell lymphoma: clinical report

Record ID 32018002218
Original Title: Tisagenlecleucel (Kymriah) for pediatric acute lymphoblastic leukemia and diffuse large b-cell lymphoma
Authors' objectives: The objectives of this clinical review were to systematically evaluate the benefits and harms of tisagenlecleucel in: (1) children and young adults with r/r B-cell ALL; and (2) adults with r/r DLBCL. This project is a component of a larger CADTH Health Technology Assessment (HTA) to assess clinical effectiveness, cost-effectiveness, patient and caregiver perspectives and experiences, ethical issues, and implementation.
Project Status: Completed
Year Published: 2019
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
MeSH Terms
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Leukemia
  • Child
  • Adolescent
  • Lymphoma, Large B-Cell, Diffuse
  • Immunotherapy, Adoptive
  • Young Adult
  • Antineoplastic Agents, Immunological
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen
  • Acute lymphoblastic leukemia
  • Pediatric
  • Child
  • CAR T-cell therapy
  • Tisagenlecleucel
  • Kymriah
  • Lymphoma
  • Adult
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca

Canadian Agency for Drugs and Technologies in Health (CADTH)

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.